CEO Diana Brainard departs; President/CFO Vikas Sinha named CEO effective Dec 19, 2024

Kalaris Therapeutics, Inc.

Diana Brainard resigned as CEO and director effective Dec 19; no disagreement with company on operations, policies, or practices.
Vikas Sinha (President, CFO since 2019) appointed CEO and principal executive officer same day; he has over 20 years life sciences finance experience.
Brainard receives $1.88M lump sum (36-mo salary), $376k target bonus, $100k merger completion bonus, and acceleration of 371,525 RSUs.
Company previously disclosed proposed merger with Kalaris Therapeutics, Inc.; Sinha served as CFO of Alexion Pharma (ALXN) previously.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.